# Anecortave Acetate Risk-Reduction Trial (AART)

> **NCT00333216** · PHASE3 · TERMINATED · sponsor: **Alcon Research** · enrollment: 24 (actual)

## Conditions studied

- AMD

## Interventions

- **DRUG:** Anecortave Acetate Sterile Suspension, 30 mg/mL
- **DRUG:** Anecortave Acetate Sterile Suspension, 60 mg/ML
- **OTHER:** Anecortave Acetate Vehicle

## Key facts

- **NCT ID:** NCT00333216
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2012-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333216, "Anecortave Acetate Risk-Reduction Trial (AART)". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00333216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*